Skip to main content

Advertisement

SpringerLink
Log in

Osteoanabolic therapy: a valid option to reduce refracture risk after vertebral augmentation procedures?

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Beall DP, Feldman RG, Gordon ML, Gruber BL, Lane JM, Valenzuela G, Yim D, Alam J, Krege JH, Krohn K (2016) Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study. Osteoporos Int 27:1191–1198. doi:10.1007/s00198-015-3353-1

    Article  CAS  PubMed  Google Scholar 

  2. Tseng YY, Su CH, Lui TN, Yeh YS, Yeh SH (2011) Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty. Osteoporos Int 23:1613–1622. doi:10.1007/s00198-011-1730-y

    Article  PubMed  PubMed Central  Google Scholar 

  3. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45:1053–1058. doi:10.1016/j.bone.2009.07.091

    Article  CAS  PubMed  Google Scholar 

  4. Li YA, Lin CL, Chang MC, Liu CL, Chen TH, Lai SC (2012) Subsequent vertebral fracture after vertebroplasty: incidence and analysis of risk factors. Spine (Phila Pa 1976) 37(3):179–183. doi:10.1097/BRS.0b013e3181f72b05

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Royal Lancaster Infirmary, Ashton Road, LA1 4RP, Lancaster, UK

    M. Massarotti & M. Bukhari

  2. Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (Milan), Italy

    M. Massarotti, G. Fabbriciani & M. De Santis

  3. Interventional Pain Unit, Galeazzi Institute, Milan, Italy

    M. Barbieri

Authors
  1. M. Massarotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Fabbriciani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Barbieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. De Santis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Bukhari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Massarotti.

Ethics declarations

Conflicts of interest

None.

Additional information

A response to these comments is available at DOI 10.1007/s00198-016-3657-9.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Massarotti, M., Fabbriciani, G., Barbieri, M. et al. Osteoanabolic therapy: a valid option to reduce refracture risk after vertebral augmentation procedures?. Osteoporos Int 27, 3387–3388 (2016). https://doi.org/10.1007/s00198-016-3659-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-016-3659-7

Keywords

Search

Navigation